Inhibikase Therapeutics (IKT) Net Equity Issued and Repurchased (2020 - 2026)

Inhibikase Therapeutics (IKT) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $2.9 million in Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $110.5 million, a 7.21% increase from a year earlier, with the FY2025 full-year figure at $107.6 million, up 4.0% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $2.9 million, down from $107.6 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for IKT reached as high as $107.6 million in Q4 2025 and fell as low as $70.0 in Q3 2023.
• Historically, Net Equity Issued and Repurchased has averaged $20.2 million across 4 years, with a median of $1.0 million in 2023.
• Across the five-year window, Net Equity Issued and Repurchased surged 22053983.85% in 2024 and tumbled 100.0% in 2025, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $452.0 in 2023, then jumped by 22053983.85% to $99.7 million in 2024, then increased by 7.96% to $107.6 million in 2025, then sank by 97.31% to $2.9 million in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $2.9 million in Q1 2026, $107.6 million in Q4 2025, and $150.0 in Q2 2025.